53 1.Cambio climático, ciencia del carbono y regulación.
Alcance 1 Emisiones de GEI ocasionadas por la combustión de gas.
Distal embolization is a relatively common phenomenon in primary PCI patients presenting with STEMI, and is associated with poor myocardial perfusion and adverse clinical outcomes. Pharmacological strategies with the use of GPIs as an adjunct to primary PCI have been demonstrated to be associated with improvements in outcomes, particularly in high-risk patients. While embolic protection devices and MGuard stents are theoretically attractive, randomized data assessing their clinical efficacy are limited. Selective manual thrombus aspiration is an attractive concept that is easy, fast, and may improve 1 year clinical outcome.
5. Henriques JPS, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization
during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-1117.
6. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies.
Eur Heart J 2001;22:729-739.
7. Shah PK. Distal embolization after percutaneous coronary interventions. Prediction, prevention and relevance. J Am Coll Cardiol 2007;50:1647-1648.
8. Haeck JDE, Koch KT, Bilodeau L, et al. Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction. The PREPARE study. JACC Cardiovasc Interv 2009;10:934-943.
9. Rentrop P, De Vivie ER, Karsch KR, et al. Acute coronary occlusion with impending infarction as angiographic complication relieved by a guide wire recanalization. Clin Cardiol 1978;1:101-106. 10. Danchin N. Systems of Care for ST-Segment Elevation Myocardial Infarction. Impact of Different
Models on Clinical Outcomes. JACC Cardiovasc Interv 2009;10:901-908.
11. Danchin N, Juilliere Y, Cherrier F. Intracoronary thrombolysis and coronary angioplasty in the acute stage of infarction. Rev Med Interne 1988;9:49-53.
12. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007;50:573-583.
13. Bekkers SCAM, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: Underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010;55:1649-1660.
14. Van’t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F; Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998;97:2302-2306. 15. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized
myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-597.
16. Brener SJ, Moliterno DJ, Aylward PE, et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur Heart J 2008;29:1127-1135.
17. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI
myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention
to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105:1909-1913.
18. De Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery
patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14
investigators. Am J Cardiol 2000;85:299-304.
19. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198. 20. Hamm CW, Heeschen C, Goldman B, et al., for the CAPTURE Investigators. Benefit of abiciximab
in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629.
21. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse
cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary
angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation
1997;96:1445-1453.
22. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients
with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using Integrilin therapy. N Engl J Med 1998:339:436-443.
CHAPTER 3.1 | 68
23. Van’t Hof AWJ, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start
of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation
(On-TIME) trial. Eur Heart J 2004;25:837-846.
24. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta analysis of randomized trials. JAMA 2005;293:1759-1765.
25. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared
with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta analysis. J Am Coll Cardiol 2009;53:1668-1673.
26. Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary
percutaneous coronary intervention: Results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 2010;56:470-475.
27. Ottani F, Vecchia LL, De Vita M, et al. Comparison by meta-analysis of eptifibatide and tirofiban
to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2010;106:167-174.
28. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive summary. A report of the American College of Cardiology Foundation/ American Heart Association Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Cathet Cardiovasc Interv 2012;79:453-495. 29. Ten Berg JM, van’t Hof AWJ, Dill T, et al. Ongoing Tirofiban In Myocardial infarction Evaluation (On-
TIME) 2 study group. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with
ST-segment elevation myocardial infarction on short and long term clinical outcome. J Am Coll Cardiol 2010;55:2446-2455.
30. Giugliano RP, White JA, Bode C, et al., for the EARLY ACS Investigators. Early versus delayed,
provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-2190.
31. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty- abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemostasis 2011;9:2361-2370.
32. Hassan AK, Liem SS, van der Kley F, et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Cathet Cardiovasc Interv 2009;74:335-343.
33. Van’t Hof AWJ, Ten Berg J, Heestermans T, et al., for the Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation
myocardial infarction undergoing primary angioplasty: a multicentre, double-blind, randomized controlled trial. Lancet 2008;372:537-546.
34. Ohlmann P, Reydel P, Jacquemin L, et al. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 2012;5:69- 76.
35. Steg Ph G, James SK, Atar D, et al. 2012 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619. 36. Goto S, Tamura N, Ishida H, et al. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi
formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004:44:316-323.
37. Moser M, Bertram U, Peter K, et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent
potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol Ther 2003;41:586-592.
38. Prati F, Capodanno D, Pawlowski T, et al. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 2010;3:928-934.
39. Stone GW, Maehara A, Witzenbichler B, et al., for the INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction. The
INFUSE-AMI Randomized Trial. JAMA 2012;307:1817-1826.
40. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 2010;22:278-282.
41. Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abiciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration. The comparison of intracoronary versus intravenous abiciximab administration during emergency reperfusion of ST segment elevation myocardial infarction (CICERO) trial. Circulation 2010;122:2709-2717.
42. Vink MA, Patterson MS, van Etten J, et al. A randomized comparison of manual versus mechanical thrombus removal in primary percutaneous coronary intervention in the treatment of ST-segment elevation myocardial infarction (TREAT-MI). Cathet Cardiovasc Interv 2011;78:14-19.
43. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-567.
44. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915-1920.
45. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009;30:2193-2203. 46. Jolly SS, on behalf of the TOTAL (A randomized Trial of Routine Aspiration thrombectomy with
Percutaneous Coronary Intervention vs PCI Alone in Patients with STEMI Undergoing Primary PCI)
trial Investigators. Clinical Trials.gov Identifier:NCT01149044.
47. Frobert O, Lagerqvist B, Gudnason T, et al. Thrombus aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. Am Heart J 2010;160:1042-1048.
48. Vlaar PJ, Svilaas T, Vogelzang M, et al. A comparison of 2 thrombus aspiration devices with histopathological analysis of retrieved material in patients presenting with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008;1:258-264.
49. Stone GW, Webb J, Cox DA, et al. Enhanced Myocardial Efficacy and Recovery by Aspiration of
Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. A randomized controlled trial. JAMA 2005;293:1063–1072.
50. Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filterbased distal
protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation (PROMISE trial). Circulation 2005;112:1462–1469.
51. Burzotta F, Testa L, Giannico F, et al. Adjunctive devices in primary or rescue PCI: a meta analysis of randomized trials. Int J Cardiol 2008;123:313-321.
52. Haeck JDE, Koch KT, Bilodeau L, et al. Randomized comparison of Primary Percutaneous Coronary Intervention with Combined Proximal Embolic Protection and Thrombus Aspiration Versus Primary Percutaneous Coronary Intervention Alone in ST-Segment Elevation Myocardial Infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST- Elevation) study. JACC Cardiovasc Interv 2009;2:934-943.
53. Vaquerizo B, Serra A, Miranda-Guardiola FM, et al. Intracoronary massive thrombosis treated with
local fibrinolysis during percutaneous coronary intervention after failed aspiration. Case series report.
Surya Dharma1, MD, Isman Firdaus1, MD, Siska S Danny1, MD, Dafsah
A Juzar1, MD, Alexander J Wardeh2, MD, J Wouter Jukema3, MD, Arnoud
van der Laarse3, MD
1 Department of Cardiology and Vascular Medicine,
Faculty of Medicine, University of Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
2 Department of Cardiology, M.C Haaglanden,
The Hague, the Netherlands
3 Department of Cardiology, Leiden University
Medical Center, Leiden, the Netherlands
Submitted